Cellectar Biosciences, Inc. — Director's Dealing 2025

Feb 18, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2025-02-14

Reporting Person: CARUSO JAMES V (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-14	Stock option (right to buy)	$0.29	A	900000	Acquired	2035-02-14	Common Stock (900000)	Direct

Footnotes

F1: This option shall vest over a period of three years from February 14, 2025, with 1/3 vesting on the first anniversary of February 14, 2026 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of February 14, 2026.